Pathogen Safety Data Sheets: Infectious Substances – Coccidioides spp.
PATHOGEN SAFETY DATA SHEET - INFECTIOUS SUBSTANCES
SECTION I - INFECTIOUS AGENT
NAME: Coccidioides spp.
CHARACTERISTICS: Coccidioides spp. are dimorphic fungi. In the environment they exist in a hyphal phase and release infectious arthroconidia (2 to 5 μm). Inside hosts, the arthroconidia transform into a unique structure called a spherule. The spherule is a large (120 μm), thick-walled structure containing 200-300 endospores, each of which can differentiate into a new endospore continuing the infection Footnote 1-Footnote 3.
SECTION II - HAZARD IDENTIFICATION
PATHOGENICITY/TOXICITY: The majority (around 60%) of individuals infected is asymptomatic or develops a very mild illness, with symptoms including cough, fever, arthralgias, myalgias, and fatigue that can last 2-6 weeks Footnote 2-Footnote 5. Symptomatic individuals develop acute pneumonia or valley fever Footnote 2. In a small percentage of cases acute pneumonia can become chronic progressive pneumonia or pulmonary nodules and cavities can develop in the lungs, characterized by pneumonia, pleural effusion, and hilar lymphadenopathy Footnote 4Footnote 5. Dissemination occurs in 1% of infections and can affect the skin, lymph nodes, bones, and joints, causing systemic symptoms such as fever, cough, and night sweats. Meningitis is the most serious complication of coccidioidomycosis, with symptoms including headache, nausea, vomiting, and affected mental status Footnote 4. This may occur in 30-50% of disseminated infections, and is fatal without treatment Footnote 1Footnote 5. Coccidioidomyces infection may also lead to erythema nodosum, acute exanthema ("Toxic erythema"), erythema multiforme, Sweet's syndrome, and interstitial granulomatous dermatitis Footnote 4.
EPIDEMIOLOGY: Coccidioides spp. are geographically limited to the alkaline soil of semiarid climates, and in regions with hot, dry summers, and low annual rainfall Footnote 2Footnote 4. C. immitis is confined mainly to California, whereas C. posadasii occurs in the southwestern United States, northern Mexico and areas of Central and South America Footnote 3. The major risk factor for infection is environmental exposure to dust and soil Footnote 1. Disseminated infection is more common among black, Asian or Filipino individuals, pregnant women in the third trimester and immunocompromised individuals Footnote 1.
HOST RANGE: Humans, nearly all mammals, and some reptiles Footnote 6.
INFECTIOUS DOSE: Estimated to be 1-10 arthroconidia Footnote 7.
MODE OF TRANSMISSION: Inhalation of arthroconidia, although secondary transmission via fomites and organ transplants may occur Footnote 1.
INCUBATION PERIOD: 1 to 3 weeks, although some infections are asymptomatic Footnote 1.
COMMUNICABILITY: Not contagious but has occasionally been transmitted from person-to-person via fomites or organ transplants Footnote 1.
SECTION III - DISSEMINATION
RESERVOIR: Soil in southwestern US, parts of Central and South America Footnote 1.
SECTION IV – STABILITY AND VIABILITY
DRUG RESISTANCE: Resistance has been observed against azoles Footnote 10. This area remains a growing concern when repeated doses are administered, especially in endemic areas.
SUSCEPTIBILITY TO DISINFECTANTS: Susceptible to 1:10 dilution of bleach, ≥6% hydrogen peroxide, 8% formaldehyde or 3% phenolics with a contact time of 20 minutes or more Footnote 7.
PHYSICAL INACTIVATION: Fungi in soil can be inactivated by heat at 120 ºC for 30 minutes Footnote 11.
SECTION V – FIRST AID / MEDICAL
SURVEILLANCE: Monitor for symptoms. Diagnosis of coccidioidomycosis can be established using serologic, histopathologic and culture methods Footnote 2Footnote 3. Skin tests can be used to identify the disease Footnote 2.
Note: All diagnostic methods are not necessarily available in all countries.
FIRST AID TREATMENT: Coccidioidomycosis is generally self-limiting and will resolve without treatment. Disseminated infections, or patients who experience excessive morbidity, should be treated with antifungal medication. The type of drug and length of treatment depends on the site of infection and clinical response Footnote 2Footnote 3Footnote 5.
PROPHYLAXIS: Exposed personnel should be given itraconazole or fluconazole (400 mg daily for 6 weeks Footnote 7.
SECTION VI - LABORATORY HAZARDS
LABORATORY-ACQUIRED INFECTIONS: 93 cases of laboratory-acquired coccidioidomycosis infections and two deaths were reported prior to 1978 Footnote 12. An additional 15 cases were asymptomatic but identified with skin tests during that period Footnote 13. One symptomatic case has been reported from 1979-2004 Footnote 14.
SOURCES / SPECIMENS: Lower respiratory tract samples, cerebrospinal fluid, sputum, skin and visceral lesions, and soil samples from infected areas (southwestern United States, parts of Central and South America) Footnote 1Footnote 2.
SPECIAL HAZARD: None.
SECTION VII – EXPOSURE CONTROLS / PERSONAL PROTECTION
RISK GROUP CLASSIFICATION: Risk group 3 Footnote 17. This risk group applies to the genus as a whole, and may not apply to every species within the genus.
CONTAINMENT REQUIREMENTS: Containment Level 3 facilities, equipment, and operational practices for work involving infectious or potentially infectious materials, animals, or cultures.
PROTECTIVE CLOTHING: Personnel entering the laboratory should remove street clothing and jewellery, and change into dedicated laboratory clothing and shoes, or don full coverage protective clothing (i.e., completely covering all street clothing). Additional protection may be worn over laboratory clothing when infectious materials are directly handled, such as solid-front gowns with tight fitting wrists, gloves, and respiratory protection. Eye protection must be used where there is a known or potential risk of exposure to splashes Footnote 18.
OTHER PRECAUTIONS: All activities with infectious material should be conducted in a biological safety cabinet (BSC) or other appropriate primary containment device in combination with personal protective equipment. Centrifugation of infected materials must be carried out in closed containers placed in sealed safety cups, or in rotors that are loaded or unloaded in a biological safety cabinet. The use of needles, syringes, and other sharp objects should be strictly limited. Open wounds, cuts, scratches, and grazes should be covered with waterproof dressings. Additional precautions should be considered with work involving animals or large scale activities Footnote 18.
SECTION VIII – HANDLING AND STORAGE
SPILLS: Allow aerosols to settle, then, wearing protective clothing, gently cover the spill with absorbent paper towel and apply appropriate disinfectant, starting at the perimeter and working towards the center. Allow sufficient contact time before starting the clean up Footnote 18.
DISPOSAL: All wastes should be decontaminated before disposal either by steam sterilization, incineration or chemical disinfection Footnote 18.
STORAGE: The infectious agent should be stored in a sealed and identified container Footnote 18.
SECTION IX – REGULATORY AND OTHER INFORMATION
REGULATORY INFORMATION: The import, transport, and use of pathogens in Canada is regulated under many regulatory bodies, including the Public Health Agency of Canada, Health Canada, Canadian Food Inspection Agency, Environment Canada, and Transport Canada. Users are responsible for ensuring they are compliant with all relevant acts, regulations, guidelines, and standards.
UPDATED: November 2010
PREPARED BY: Pathogen Regulation Directorate, Public Health Agency of Canada
Although the information, opinions and recommendations contained in this Pathogen Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.
Public Health Agency of Canada, 2010
Report a problem or mistake on this page
- Date modified: